New chikungunya cases in Europe fuel false vaccine claims
While some social media users promoted chikungunya vaccines, others falsely claimed that all vaccines are unsafe.
As a mosquito-borne virus spreads in Europe, social media users are discussing its symptoms and the vaccines that protect against it.
Insights brought to you by the reporters and science writers of Public Good News (PGN), a nonprofit newsroom dedicated to improving community health.
In late July, the World Health Organization issued a warning about chikungunya, a potentially serious mosquito-borne virus that is spreading in Europe and on other continents. Facebook users in several European countries discussed recent cases in Germany, France, and Italy; expressed fear about severe symptoms; and encouraged people to get vaccinated against the disease. Some commenters on Facebook posts sharing articles about chikungunya falsely claimed that chikungunya vaccines are unsafe, noting that in May, the European Medicines Agency temporarily restricted use of IXCHIQ—a chikungunya vaccine—in people ages 65 and older while conducting further safety reviews. However, EMA lifted the restriction on July 24. Commenters also falsely claimed that all vaccines are “poison,” with many citing unfounded concerns about COVID-19 vaccine safety.
Recommendations brought to you by the health communication experts behind Infodemiology.com.
Health messaging recommendations
Each week, the Infodemiology.com team will provide messaging recommendations in response to some of the trending narratives outlined above. These helpful tips can be used when creating content, updating web and FAQ pages, and developing strategy for messaging about health.
In response to online conversation about chikungunya, messaging may explain that chikungunya is a virus that mosquitos can transmit to humans and that the virus does not spread from person to person. Health care providers and public health communicators may outline common symptoms, including fever, severe joint pain, headache, nausea, fatigue, and rash. Messaging may highlight that chikungunya is especially dangerous for babies and older adults, who are at increased risk of severe symptoms and death. Messaging may emphasize that available chikungunya vaccines have been rigorously tested to ensure safety and explain that the vaccine is only recommended for certain high-risk populations. Encouraging individuals to talk to their health care provider to determine if they are eligible for the chikungunya vaccine is recommended. Additionally, messaging may note that taking steps to prevent mosquito bites—like using insect repellent and wearing long-sleeved shirts and pants outdoors—helps protect against chikungunya and other mosquito-borne diseases.